Marc Hickel thought his battle with prostate cancer was over after surgery and radiation treatment. But five years later, ...

Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...

Companies working on new medicines to treat obesity and a new approach to using artificial intelligence in science labs are ...

Cancer survivor Marc Hickel found relief from debilitating post-radiation complications through hyperbaric oxygen therapy at ...

At this stage of life, it's vital to lift weights, avoid getting too thin, reduce alcohol and keep up to date with jabs ...

TWELVE members of the East Cornwall Harriers are preparing to take on the challenging Cornish Marathon on November 2, running in support of fellow club member Craig Vaughnley, who is currently ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk ...

BERLIN — In June, Amgen reported that an experimental drug had hit the main goal of a gastric cancer study, improving overall ...

A spokesperson for Joe Biden says the former Democratic president has completed several weeks of radiation therapy to treat ...

Competitive bidding for catheters means reduced patient choice, jeopardized supply chains, and an incentive to push cheap, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...